Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Colorectal Neoplasms 2678Pancreatic Neoplasms 1470Colonic Neoplasms 1159Carcinoma, Hepatocellular 1142Stomach Neoplasms 1127Rectal Neoplasms 980Esophageal Neoplasms 728Neoplasms 559Liver Neoplasms 533Breast Neoplasms 473Neoplasm Metastasis 373Lung Neoplasms 325Carcinoma, Non-Small-Cell Lung 292Gastrointestinal Neoplasms 277Ovarian Neoplasms 258Prostatic Neoplasms 229Cholangiocarcinoma 221Head and Neck Neoplasms 180Gastrointestinal Stromal Tumors 176Melanoma 165Esophageal Squamous Cell Carcinoma 164Barrett Esophagus 156Uterine Cervical Neoplasms 151Biliary Tract Neoplasms 149Adenocarcinoma Of Esophagus 148Gallbladder Neoplasms 136Carcinoma, Renal Cell 134Urinary Bladder Neoplasms 132Sarcoma 131Anus Neoplasms 124

Interventions

bintrafusp alfa protein, human 1Sorafenib 1LY-2157299 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Camurati-Engelmann Syndrome × Gastrointestinal × Clear all
NCT03833661 2023-10-25

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

EMD Serono

Phase 2 Completed
159 enrolled 23 charts
Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

NCT02178358 2022-02-25

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Eli Lilly and Company

Phase 2 Completed
132 enrolled 25 charts
Gastrointestinal

Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡